Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other ...

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

Dec. 2, 2024 — Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease (CHD), according to ...

Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights. "As ...

Dec. 5, 2024 — The fungus that causes coffee wilt disease repeatedly took up segments of DNA from a related fungal pathogen, which contributed to successive ...

Pitcairn Co. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 3rd quarter, ...

Investing.com - Denali Therapeutics (NASDAQ: DNLI) reported fourth quarter EPS of $-0.75, $0.04 better than the analyst estimate of $-0.79. Revenue for the quarter came in at ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Buy DNLI near 22.91 target 26.85 stop loss @ 22.84 Details The technical summary data tells us to buy DNLI near 22.91 with an upside target of 26.85. This data also tells us to set a stop loss @ 22.84 ...